Search

Your search keyword '"Fredi, Micaela"' showing total 371 results
Start Over Author "Fredi, Micaela"
371 results on '"Fredi, Micaela"'

1. Overview on CTD in the Elderly

Author

Lini, Daniele, Semeraro, Paolo, Fredi, Micaela, Campana, Andrea, Gozzoli, Giorgia, Piovani, Elda, Andreoli, Laura, Franceschini, Franco, Emmi, Lorenzo, Series Editor, Prisco, Domenico, Series Editor, Salvarani, Carlo, Editorial Board Member, Sinico, Renato Alberto, Editorial Board Member, Meroni, Pier Luigi, Editorial Board Member, Roccatello, Dario, Editorial Board Member, Matucci-Cerinic, Marco, Editorial Board Member, Gattorno, Marco, Editorial Board Member, de Benedetti, Fabrizio, Editorial Board Member, Cimaz, Rolando, Editorial Board Member, Plebani, Alessandro, Editorial Board Member, Baldari, Cosima Tatiana, Editorial Board Member, D'Elios, Mario Milco, Editorial Board Member, and Vaglio, Augusto, Editorial Board Member

Published
2024
Full Text
View/download PDF

2. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Author

Ugarte-Gil, Manuel Francisco, Alarcón, Graciela S, Izadi, Zara, Duarte-García, Ali, Reátegui-Sokolova, Cristina, Clarke, Ann Elaine, Wise, Leanna, Pons-Estel, Guillermo J, Santos, Maria Jose, Bernatsky, Sasha, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Gilbert, Emily L, Valenzuela-Almada, Maria O, Jönsen, Andreas, Landolfi, Gianpiero, Fredi, Micaela, Goulenok, Tiphaine, Devaux, Mathilde, Mariette, Xavier, Queyrel, Viviane, Romão, Vasco C, Sequeira, Graca, Hasseli, Rebecca, Hoyer, Bimba, Voll, Reinhard E, Specker, Christof, Baez, Roberto, Castro-Coello, Vanessa, Ficco, Hernan Maldonado, Neto, Edgard Torres Reis, Ferreira, Gilda Aparecida Aparecida, Monticielo, Odirlei Andre André, Sirotich, Emily, Liew, Jean, Hausmann, Jonathan, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Jacobsohn, Lindsay, Taylor, Tiffany, Ja, Clairissa, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schäfer, Martin, Machado, Pedro M, Robinson, Philip C, Gianfrancesco, Milena, and Yazdany, Jinoos

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Infectious Diseases, Lupus, Emerging Infectious Diseases, Minority Health, Coronaviruses, Autoimmune Disease, Women's Health, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, COVID-19, Humans, Lupus Erythematosus, Systemic, Male, Prednisone, Rheumatology, Severity of Illness Index, lupus erythematosus, systemic, epidemiology, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

AimTo determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19.MethodsPeople with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity.ResultsA total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab.ConclusionsMore severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.

Published
2022

4. A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence

Author

Bruschi, Maurizio, Angeletti, Andrea, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavalli, Andrea, Scapozza, Leonardo, Patel, Jigar J., Tan, John C., Lo, Ken C., Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Giannese, Domenico, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisan, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mescia, Federica, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Ravelli, Angelo, Murtas, Corrado, Candiano, Giovanni, Caridi, Gianluca, La Porta, Edoardo, and Verrina, Enrico

Published
2024
Full Text
View/download PDF

6. Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study

Author

Tani, Chiara, Cardelli, Chiara, Depascale, Roberto, Gamba, Anna, Iaccarino, Luca, Doria, Andrea, Bandeira, Matilde, Dinis, Sara Paiva, Romão, Vasco C., Gotelli, Emanuele, Paolino, Sabrina, Cutolo, Maurizio, Di Giosaffatte, Niccolò, Ferraris, Alessandro, Grammatico, Paola, Cavagna, Lorenzo, Codullo, Veronica, Montecucco, Carlomaurizio, Longo, Valentina, Beretta, Lorenzo, Cavazzana, Ilaria, Fredi, Micaela, Peretti, Silvia, Guiducci, Serena, Matucci-Cerinic, Marco, Bombardieri, Stefano, Burmester, Gerd R., Fonseca, João E., Frank, Charissa, Galetti, Ilaria, Hachulla, Eric, Müller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Tamirou, Farah, Van Laar, Jacob M., Vieira, Ana, D'Urzo, Rossella, Cannizzo, Sara, Gaglioti, Andrea, Marinello, Diana, Talarico, Rosaria, and Mosca, Marta

Published
2023
Full Text
View/download PDF

8. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Author

Fredi, Micaela, Cavazzana, Ilaria, Ceribelli, Angela, Cavagna, Lorenzo, Barsotti, Simone, Bartoloni, Elena, Benucci, Maurizio, De Stefano, Ludovico, Doria, Andrea, Emmi, Giacomo, Fabris, Martina, Fornaro, Marco, Furini, Federica, Giudizi, Maria Grazia, Govoni, Marcello, Ghirardello, Anna, Iaccarino, Luca, Iannone, Fiorenzo, Infantino, Maria, Isailovic, Natasa, Lazzaroni, Maria Grazia, Manfredi, Mariangela, Mathieu, Alessandro, Marasco, Emiliano, Migliorini, Paola, Montecucco, Carlomaurizio, Palterer, Boaz, Parronchi, Paola, Piga, Matteo, Pratesi, Federico, Riccieri, Valeria, Selmi, Carlo, Tampoia, Marilina, Tripoli, Alessandra, Zanframundo, Giovanni, Radice, Antonella, Gerli, Roberto, and Franceschini, Franco

Published
2022
Full Text
View/download PDF

9. Comparison of Lineblot and Immunoprecipitation Methods in the Detection of Myositis-Specific and Myositis-Associated Antibodies in Patients with Idiopathic Inflammatory Myopathies: Consistency with Clinical Diagnoses.

Author

Angeli, Fabrizio, Pedretti, Eleonora, Garrafa, Emirena, Fredi, Micaela, Ceribelli, Angela, Franceschini, Franco, and Cavazzana, Ilaria

Subjects
IDIOPATHIC diseases, POLYMYOSITIS, DERMATOMYOSITIS, AUTOANTIBODIES, IMMUNOPRECIPITATION
Abstract

Background: the reference method for detection of myositis-specific and myositis-associated antibodies (MSAs and MAAs) is considered immunoprecipitation (IP), but it is routinely replaced by semi-automated methods, like lineblot (LB). Few data are available on the consistency with clinical diagnoses; thus, we aim at analysing these aspects. Methods: sixty-nine patients with idiopathic inflammatory myopathies (IIM) were studied via LB (Myositis Antigens Profile 3 EUROLINE, Euroimmun) and IP (RNA and protein antigens). The degree of concordance between methods was calculated using Cohen's coefficient. Results: a substantial concordance was found for anti-Ku and anti-PM/Scl and a moderate concordance was found for anti-Jo1 and anti–Mi-2, while a fair concordance was found for anti-EJ, anti-SRP, and anti-Ro52 antibodies. The concordance could not be calculated for anti-OJ, anti-PL-7, anti-PL-12, anti-NXP2, anti-TIF1ɣ, and anti-MDA5, because they were only detected with one method. Multiple MSAs were found only with LB in 2/69 sera. Anti-MDA5, TIF1ɣ, NXP2 (detected via IP), and anti-Jo1 in anti-synthetase syndrome (both LB and IP) had the best concordance with clinical diagnosis. Conclusions: LB and IP show substantial concordance for PM/Scl and Ku, and moderate concordance for Jo1 and Mi-2, with a good concordance with clinical diagnoses. IP shows a high performance for DM-associated MSAs. LB seems to be more sensitive in detecting anti-Ro52 antibodies, but it identified multiple MSAs, unlike IP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study.

Author

Bortoluzzi, Alessandra, Fanouriakis, Antonis, Silvagni, Ettore, Appenzeller, Simone, Carli, Linda, Carrara, Greta, Cauli, Alberto, Conti, Fabrizio, Costallat, Lilian Teresa Lavras, Marchi, Ginevra De, Doria, Andrea, Fredi, Micaela, Franceschini, Franco, Garaffoni, Carlo, Hanly, John G, Mosca, Marta, Murphy, Elana, Piga, Matteo, Quartuccio, Luca, and Scirè, Carlo Alberto

Subjects
SCALE analysis (Psychology), ADRENOCORTICAL hormones, NEUROLOGIC manifestations of general diseases, IMMUNOSUPPRESSIVE agents, RECEIVER operating characteristic curves, LOGISTIC regression analysis, SYSTEMIC lupus erythematosus, SEVERITY of illness index, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, LONGITUDINAL method, ODDS ratio, RESEARCH, CONFIDENCE intervals, ALGORITHMS
Abstract

Objectives The management of neuropsychiatric systemic lupus erythematosus (NPSLE) poses considerable challenges due to limited clinical trials. Therapeutic decisions are customized based on suspected pathogenic mechanisms and symptoms severity. This study aimed to investigate therapeutic strategies and disease outcome for patients with NPSLE experiencing their first neuropsychiatric (NP) manifestation. Methods This retrospective cohort study defined NP events according to the American College of Rheumatology case definition, categorizing them into three clusters: central/diffuse, central/focal and peripheral. Clinical judgment and a validated attribution algorithm were used for NP event attribution. Data included demographic variables, SLE disease activity index, cumulative organ damage, and NP manifestation treatments. The clinical outcome of all NP events was determined by a physician seven-point Likert scale. Predictors of clinical improvement/resolution were investigated in a multivariable logistic regression analysis. Results The analysis included 350 events. Immunosuppressants and corticosteroids were more frequently initiated/escalated for SLE-attributed central diffuse or focal NP manifestations. At 12 months of follow-up, 64% of patients showed a clinical improvement in NP manifestations. Focal central events and SLE-attributed manifestations correlated with higher rates of clinical improvement. Patients with NP manifestations attributed to SLE according to clinical judgment and treated with immunosuppressants had a significantly higher probability of achieving clinical response (OR 2.55, 95%CI 1.06–6.41, P  = 0.04). Age at diagnosis and focal central events emerged as additional response predictors. Conclusion NP manifestations attributed to SLE by clinical judgment and treated with immunosuppressants demonstrated improved 12-month outcomes. This underscores the importance of accurate attribution and timely diagnosis of NPSLE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. P138 Pregnancy outcomes in SLE patients treated with belimumab: the Italian experience

Author

Crisafulli, Francesca, primary, Gerardi, Maria Chiara, additional, Urban, Maria Letizia, additional, Zen, Margherita, additional, Padovan, Melissa, additional, Canti, Valentina, additional, Praino, Emanuela, additional, Gerosa, Maria, additional, Nalli, Cecilia, additional, Ruffilli, Francesca, additional, Saccon, Francesca, additional, Fredi, Micaela, additional, Emmi, Giacomo, additional, Iaccarino, Luca, additional, Doria, Andrea, additional, Santo, Leonardo, additional, Franceschini, Franco, additional, Andreoli, Laura, additional, and Tincani, Angela, additional

Published
2024
Full Text
View/download PDF

13. P39 Analysis of nailfold capillaroscopy findings and clinical features of patients with systemic lupus erythematosus and pulmonary arterial hypertension

Author

Marasco, Emiliano, primary, Duesing, Christina, additional, Keymel, Stephanie, additional, Zanframundo, Giovanni, additional, Codullo, Veronica, additional, Sander, Oliver, additional, Chehab, Gamal, additional, Richter, Jutta, additional, Fischer-Betz, Rebecca, additional, Bracaglia, Claudia, additional, Sahin, Sezgin, additional, Triantafyllias, Konstantinos, additional, Schwarting, Andreas, additional, Keller, Lisa, additional, Meyer, Alain, additional, Canuet, Matthieu, additional, Riou, Marianne, additional, Cavazzana, Ilaria, additional, Fredi, Micaela, additional, Franceschini, Franco, additional, Silvagni, Ettore, additional, Bortoluzzi, Alessandra, additional, Scirè, Carlo Alberto, additional, Montecucco, Carlomaurizio, additional, Cavagna, Lorenzo, additional, and Schneider, Matthias, additional

Published
2024
Full Text
View/download PDF

14. P64 Evaluation of changes in SLE patients’ phenotype at disease onset, and assessment of disease activity, damage and therapy at diagnosis and during follow up in the last forty years: preliminary data of a single center experience

Author

Fredi, Micaela, primary, Lucia Della Pina, Silvia Ebe, additional, Barison, Claudia, additional, Orlandi, Chiara, additional, Tedeschi, Marzia, additional, Mai, Chiara, additional, Nalli, Cecilia, additional, and Franceschini, Franco, additional

Published
2024
Full Text
View/download PDF

17. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study

Author

Airò, Paolo, Bazzani, Chiara, Crisafulli, Francesca, Filippini, Matteo, Frassi, Micol, Gerardi, Maria Chiara, Gorla, Roberto, Lazzaroni, Maria Grazia, Lini, Daniele, Nalli, Cecilia, Panaro, Salvatore, Piantoni, Silvia, Regola, Francesca, Taglietti, Marco, Tincani, Angela, Toniati, Paola, Vojinovic, Tamara, Zingarelli, Stefania, Fredi, Micaela, Cavazzana, Ilaria, Moschetti, Liala, Andreoli, Laura, and Franceschini, Franco

Published
2020
Full Text
View/download PDF

18. Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?

Author

Andreoli, Laura, primary, Regola, Francesca, additional, Caproli, Alessia, additional, Crisafulli, Francesca, additional, Fredi, Micaela, additional, Lazzaroni, Maria-Grazia, additional, Nalli, Cecilia, additional, Piantoni, Silvia, additional, Zatti, Sonia, additional, Franceschini, Franco, additional, and Tincani, Angela, additional

Published
2024
Full Text
View/download PDF

20. Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic

Author

García-Fernández, Antía, Gerardi, Maria Chiara, Crisafulli, Francesca, Filippini, Matteo, Fredi, Micaela, Gorla, Roberto, Lazzaroni, Maria Grazia, Lojacono, Andrea, Nalli, Cecilia, Ramazzotto, Francesca, Taglietti, Marco, Zanardini, Cristina, Zatti, Sonia, Franceschini, Franco, Tincani, Angela, and Andreoli, Laura

Published
2021
Full Text
View/download PDF

21. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospective Italian P-RHEUM. it study.

Author

Andreoli, Laura, Gerardi, Maria Chiara, Gerosa, Maria, Rozza, Davide, Crisafulli, Francesca, Erra, Roberta, Lini, Daniele, Trespidi, Laura, Padovan, Melissa, Ruffilli, Francesca, Serale, Francesca, Cuomo, Giovanna, Raffeiner, Bernd, Semeraro, Paolo, Tani, Chiara, Chimenti, Maria Sole, Conigliaro, Paola, Hoxha, Ariela, Nalli, Cecilia, and Fredi, Micaela

Published
2024
Full Text
View/download PDF

22. Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis

Author

Carini, Mattia, primary, Fredi, Micaela, additional, Cavazzana, Ilaria, additional, Bresciani, Roberto, additional, Ferrari, Fabiana, additional, Monti, Eugenio, additional, Franceschini, Franco, additional, and Biasiotto, Giorgio, additional

Published
2023
Full Text
View/download PDF

23. Autoimmune polyglandular syndrome type 4: experience from a single reference center

Author

Gatta, Elisa, primary, Anelli, Valentina, additional, Cimino, Elena, additional, Di Lodovico, Elena, additional, Piovani, Elda, additional, Zammarchi, Irene, additional, Gozzoli, Giorgia, additional, Maltese, Virginia, additional, Cavadini, Maria, additional, Agosti, Barbara, additional, Delbarba, Andrea, additional, Pirola, Ilenia, additional, Girelli, Angela, additional, Buoso, Caterina, additional, Bambini, Francesca, additional, Alfieri, Daniele, additional, Bremi, Walter, additional, Facondo, Paolo, additional, Lupo, Roberto, additional, Bezzi, Francesco, additional, Fredi, Micaela, additional, Mazzola, Anna Maria, additional, Gandossi, Elena, additional, Saullo, Maura, additional, Marini, Fiorella, additional, Licini, Massimo, additional, Pezzaioli, Letizia Chiara, additional, Pini, Laura, additional, Franceschini, Franco, additional, Ricci, Chiara, additional, and Cappelli, Carlo, additional

Published
2023
Full Text
View/download PDF

24. COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology

Author

Scirocco, Chiara, primary, Ferrigno, Sara, additional, Andreoli, Laura, additional, Fredi, Micaela, additional, Lomater, Claudia, additional, Moroni, Luca, additional, Mosca, Marta, additional, Raffeiner, Bernd, additional, Carrara, Greta, additional, Landolfi, Gianpiero, additional, Rozza, Davide, additional, Zanetti, Anna, additional, Scirè, Carlo Alberto, additional, and Sebastiani, Gian Domenico, additional

Published
2023
Full Text
View/download PDF

27. Systemic Vasculitis and Pregnancy

Author

Lazzaroni, Maria Grazia, Fredi, Micaela, Zatti, Sonia, Lojacono, Andrea, Tincani, Angela, Dammacco, Franco, editor, Ribatti, Domenico, editor, and Vacca, Angelo, editor

Published
2016
Full Text
View/download PDF

28. Obstetric APS

Author

Fredi, Micaela, Tincani, Angela, Emmi, Lorenzo, Series editor, Prisco, Domenico, Series editor, and Meroni, Pier Luigi, editor

Published
2015
Full Text
View/download PDF

29. Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)

Author

Zen, Margherita, primary, Gatto, Mariele, additional, Depascale, Roberto, additional, Regola, Francesca, additional, Fredi, Micaela, additional, Andreoli, Laura, additional, Franceschini, Franco, additional, Urban, Maria Letizia, additional, Emmi, Giacomo, additional, Ceccarelli, Fulvia, additional, Conti, Fabrizio, additional, Bortoluzzi, Alessandra, additional, Govoni, Marcello, additional, Tani, Chiara, additional, Mosca, Marta, additional, Ubiali, Tania, additional, Gerosa, Maria, additional, Bozzolo, Enrica P., additional, Canti, Valentina, additional, Cardinaletti, Paolo, additional, Gabrielli, Armando, additional, Tanti, Giacomo, additional, Gremese, Elisa, additional, De Marchi, Ginevra, additional, De Vita, Salvatore, additional, Fasano, Serena, additional, Ciccia, Francesco, additional, Pazzola, Giulia, additional, Salvarani, Carlo, additional, Negrini, Simone, additional, Di Matteo, Andrea, additional, De Angelis, Rossella, additional, Orsolini, Giovanni, additional, Rossini, Maurizio, additional, Faggioli, Paola, additional, Laria, Antonella, additional, Piga, Matteo, additional, Cauli, Alberto, additional, Scarpato, Salvatore, additional, Rossi, Francesca Wanda, additional, De Paulis, Amato, additional, Brunetta, Enrico, additional, Ceribelli, Angela, additional, Selmi, Carlo, additional, Prete, Marcella, additional, Racanelli, Vito, additional, Vacca, Angelo, additional, Bartoloni, Elena, additional, Gerli, Roberto, additional, Zanatta, Elisabetta, additional, Larosa, Maddalena, additional, Saccon, Francesca, additional, Doria, Andrea, additional, and Iaccarino, Luca, additional

Published
2023
Full Text
View/download PDF

30. Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis

Author

Galli, Jessica, Gavazzi, Francesco, De Simone, Micaela, Giliani, Silvia, Garau, Jessica, Valente, Marialuisa, Vairo, Donatella, Cattalini, Marco, Mortilla, Marzia, Andreoli, (Laura, Badolato, Raffaele, Bianchi, Marika, Carabellese, Nice, Cereda, Cristina, Ferraro, Rosalba, Facchetti, Fabio, Fredi, Micaela, Gualdi, Giulio, Lorenzi, Luisa, Meini, Antonella, Orcesi, Simona, Tincani, Angela, Zanola, Alessandra, Rice, Gillian, and Fazzi, Elisa

Published
2018
Full Text
View/download PDF

31. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study

Author

Floris, Alberto, primary, Chessa, Elisabetta, additional, Sebastiani, Gian Domenico, additional, Prevete, Immacolata, additional, Iannone, Florenzo, additional, Coladonato, Laura, additional, Govoni, Marcello, additional, Bortoluzzi, Alessandra, additional, Mosca, Marta, additional, Tani, Chiara, additional, Doria, Andrea, additional, Iaccarino, Luca, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Bellisai, Francesca, additional, D'Alessandro, Roberto, additional, Zanetti, Anna, additional, Carrara, Greta, additional, Scirè, Carlo Alberto, additional, Cauli, Alberto, additional, and Piga, Matteo, additional

Published
2022
Full Text
View/download PDF

34. Evidence for charge-based mimicry in anti dsDNA antibody generation

Author

Bruschi, Maurizio, primary, Angeletti, Andrea, additional, Kajana, Xhuliana, additional, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Fredi, Micaela, additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Locatelli, Francesco, additional, Pazzola, Giulia, additional, Pesce, Giampaola, additional, Bagnasco, Marcello, additional, Manfredi, Angelo, additional, Ramirez, Giuseppe Alvise, additional, Esposito, Pasquale, additional, Negrini, Simone, additional, Bui, Federica, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Cavazzana, Ilaria, additional, Binda, Valentina, additional, Fenaroli, Paride, additional, Pisani, Isabella, additional, Montecucco, Carlomaurizio, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Volpi, Stefano, additional, Mosca, Marta, additional, Tincani, Angela, additional, Candiano, Giovanni, additional, Verrina, Enrico, additional, Franceschini, Franco, additional, Ravelli, Angelo, additional, Prunotto, Marco, additional, Meroni, Pier Luigi, additional, and Ghiggeri, Gian Marco, additional

Published
2022
Full Text
View/download PDF

36. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.

Author

Filippini, Federica, Giacomelli, Mauro, Bazzani, Chiara, Fredi, Micaela, Semeraro, Paolo, Tomasi, Cesare, Franceschini, Franco, Caruso, Arnaldo, Cavazzana, Ilaria, and Giagulli, Cinzia

Subjects
HUMORAL immunity, AUTOIMMUNE diseases, COVID-19 vaccines, RITUXIMAB, COMMON variable immunodeficiency, IMMUNOSUPPRESSIVE agents, TITERS, T cells
Abstract

Background: The impact of immunosuppressive therapies on the efficacy of vaccines to SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated response after COVID-19 mRNA vaccine in immunosuppressed patients and patients with common variable immunodeficiency disease (CVID). Patients: We enrolled 38 patients and 11 healthy sex- and age-matched controls (HC). Four patients were affected by CVID and 34 by chronic rheumatic diseases (RDs). All patients with RDs were treated by corticosteroid therapy and/or immunosuppressive treatment and/or biological drugs: 14 patients were treated with abatacept, 10 with rituximab, and 10 with tocilizumab. Methods: Total antibody titer to SARS-CoV-2 spike protein was assessed by electrochemiluminescence immunoassay, CD4 and CD4-CD8 T cell-mediated immune response was analyzed by interferon-γ (IFN-γ) release assay, the production of IFN-γ-inducible (CXCL9 and CXCL10) and innate-immunity chemokines (MCP-1, CXCL8, and CCL5) by cytometric bead array after stimulation with different spike peptides. The expression of CD40L, CD137, IL-2, IFN-γ, and IL-17 on CD4 and CD8 T cells, evaluating their activation status, after SARS-CoV-2 spike peptides stimulation, was analyzed by intracellular flow cytometry staining. Cluster analysis identified cluster 1, namely the "high immunosuppression" cluster, and cluster 2, namely the "low immunosuppression" cluster. Results: After the second dose of vaccine, only abatacept-treated patients, compared to HC, showed a reduced anti-spike antibody response (mean: 432 IU/ml ± 562 vs mean: 1479 IU/ml ± 1051: p = 0.0034), and an impaired T cell response, compared with HC. In particular, we found a significantly reduced release of IFN-γ from CD4 and CD4-CD8 stimulated T cells, compared with HC (p = 0.0016 and p = 0.0078, respectively), reduced production of CXCL10 and CXCL9 from stimulated CD4 (p = 0.0048 and p = 0.001) and CD4-CD8 T cells (p = 0.0079 and p = 0.0006). Multivariable General Linear Model analysis confirmed a relationship between abatacept exposure and impaired production of CXCL9, CXCL10, and IFN-γ from stimulated T cells. Cluster analysis confirms that cluster 1 (including abatacept and half of rituximab treated cases) showed a reduced IFN-γ response, as well as reduced monocyte-derived chemokines All groups of patients demonstrated the ability to generate specific CD4 T activated cells after spike proteins stimulation. After the third dose of vaccine, abatacept-treated patients acquired the ability to produce a strong antibody response, showing an anti-S titer significantly higher compared to that obtained after the second dose (p = 0.0047), and comparable with the anti-S titer of the other groups. Conclusions: Patients treated with abatacept showed an impaired humoral immune response to two doses of COVID-19 vaccine. The third vaccine dose has been demonstrated to be useful to induce a more robust antibody response to balance an impaired T cell-mediated one. All patients, exposed to different immunosuppressive drugs, were able to produce specific CD4-activated T cells, after spike proteins stimulation. Trial registration: Local Ethical Committee NP4187. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis

Author

Gatto Mariele, Larosa Maddalena, Doria. Andrea, Loredo Martinez Marta, Fredi Micaela, Zen Margherita, Iaccarino Luca, Saccon Francesca, Depascale Roberto, and Fuzzi Enrico

Subjects
Adult, Male, medicine.medical_specialty, Biopsy, Lupus nephritis, Disease, antimalarials, drug discontinuation, immunosuppressants, lupus nephritis, remission, systemic lupus erythematosus, Kidney, Gastroenterology, chemistry.chemical_compound, Rheumatology, Maintenance therapy, Recurrence, Internal medicine, medicine, Humans, Pharmacology (medical), In patient, Creatinine, Proteinuria, medicine.diagnostic_test, business.industry, Remission Induction, Middle Aged, medicine.disease, Lupus Nephritis, Discontinuation, Logistic Models, chemistry, Prednisone, Female, Renal biopsy, medicine.symptom, business, Immunosuppressive Agents
Abstract

Objectives Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis (LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients with LN in remission. Methods Patients with biopsy-proven LN treated with immunosuppressants (IS) between 1980 and 2020 were considered. Remission was defined as normal serum creatinine, proteinuria Results Among 513 SLE patients included in our database, 270 had LN. Of them, 238 underwent renal biopsy and were treated with IS. Eighty-three patients (34.8%) discontinued IS, 46 (30) months after remission achievement. During a mean (s.d.) follow-up of 116.5 (78) months, 19 patients (22.9%) developed a flare (8/19 renal) and were re-treated; 14/19 (73.7%) re-achieved remission after restarting therapy. Patients treated with IS therapy for at least 3 years after remission achievement had the lowest risk of relapse (OR 0.284, 95% CI: 0.093, 0.867; P = 0.023). At multivariate analysis, antimalarial maintenance therapy (OR 0.194, 95% CI: 0.038, 0.978; P = 0.047), age at IS discontinuation (OR 0.93, 95% CI: 0.868, 0.997; P = 0.040), remission duration >3 years before IS discontinuation (OR 0.231, 95% CI: 0.058, 0.920; P = 0.038) were protective against disease flares. Conclusions Withdrawal of IS is feasible in LN patients in remission for at least 3 years and on antimalarial therapy. Patients who experience flares can re-achieve remission with an appropriate treatment.

Published
2021

42. Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis

Author

Gerardi, Maria Chiara, primary, Crisafulli, Francesca, additional, García-Fernandez, Antía, additional, Lini, Daniele, additional, Bazzani, Chiara, additional, Cavazzana, Ilaria, additional, Filippini, Matteo, additional, Fredi, Micaela, additional, Gorla, Roberto, additional, Lazzaroni, Maria Grazia, additional, Nalli, Cecilia, additional, Taglietti, Marco, additional, Lojacono, Andrea, additional, Ramazzotto, Francesca, additional, Zanardini, Cristina, additional, Zatti, Sonia, additional, Franceschini, Franco, additional, Tincani, Angela, additional, and Andreoli, Laura, additional

Published
2022
Full Text
View/download PDF

43. Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Author

Ferri, Clodoveo, primary, Antonelli, Alessandro, primary, Raimondo, Vincenzo, additional, Gragnani, Laura, additional, Giuggioli, Dilia, additional, Dagna, Lorenzo, additional, Tavoni, Antonio, additional, Ursini, Francesco, additional, L'Andolina, Massimo, additional, Caso, Francesco, additional, Ruscitti, Piero, additional, Caminiti, Maurizio, additional, Foti, Rosario, additional, Riccieri, Valeria, additional, Guiducci, Serena, additional, Pellegrini, Roberta, additional, Zanatta, Elisabetta, additional, Varcasia, Giuseppe, additional, Olivo, Domenico, additional, Gigliotti, Pietro, additional, Cuomo, Giovanna, additional, Murdaca, Giuseppe, additional, Cecchetti, Riccardo, additional, De Angelis, Rossella, additional, Romeo, Nicoletta, additional, Ingegnoli, Francesca, additional, Cozzi, Franco, additional, Codullo, Veronica, additional, Cavazzana, Ilaria, additional, Colaci, Michele, additional, Abignano, Giuseppina, additional, De Santis, Maria, additional, Lubrano, Ennio, additional, Fusaro, Enrico, additional, Spinella, Amelia, additional, Lumetti, Federica, additional, De Luca, Giacomo, additional, Bellando-Randone, Silvia, additional, Visalli, Elisa, additional, Bosco, Ylenia Dal, additional, Amato, Giorgio, additional, Giannini, Daiana, additional, Bilia, Silvia, additional, Masini, Francesco, additional, Pellegrino, Greta, additional, Pigatto, Erika, additional, Generali, Elena, additional, Mariano, Giuseppa Pagano, additional, Pettiti, Giorgio, additional, Zanframundo, Giovanni, additional, Brittelli, Raffaele, additional, Aiello, Vincenzo, additional, Caminiti, Rodolfo, additional, Scorpiniti, Daniela, additional, Ferrari, Tommaso, additional, Campochiaro, Corrado, additional, Brusi, Veronica, additional, Fredi, Micaela, additional, Moschetti, Liala, additional, Cacciapaglia, Fabio, additional, Paparo, Sabrina Rosaria, additional, Ragusa, Francesca, additional, Mazzi, Valeria, additional, Elia, Giusy, additional, Ferrari, Silvia Martina, additional, Di Cola, Ilenia, additional, Vadacca, Marta, additional, Lorusso, Sebastiano, additional, Monti, Monica, additional, Lorini, Serena, additional, Aprile, Maria Letizia, additional, Tasso, Marco, additional, Miccoli, Mario, additional, Bosello, Silvia, additional, D'Angelo, Salvatore, additional, Doria, Andrea, additional, Franceschini, Franco, additional, Meliconi, Riccardo, additional, Matucci-Cerinic, Marco, additional, Iannone, Florenzo, additional, Giacomelli, Roberto, additional, Salvarani, Carlo, additional, Zignego, Anna Linda, additional, and Fallahi, Poupak, additional

Published
2022
Full Text
View/download PDF

44. Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Author

Ferri, Clodoveo, Raimondo, Vincenzo, Gragnani, Laura, Giuggioli, Dilia, Dagna, Lorenzo, Tavoni, Antonio, Ursini, Francesco, L'Andolina, Massimo, Caso, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Bosco, Ylenia Dal, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Monti, Monica, Lorini, Serena, Aprile, Maria Letizia, Tasso, Marco, Miccoli, Mario, Bosello, Silvia Laura, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Matucci-Cerinic, Marco, Iannone, Florenzo, Giacomelli, Roberto, Salvarani, Carlo, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, Bosello, Silvia (ORCID:0000-0002-4837-447X), Ferri, Clodoveo, Raimondo, Vincenzo, Gragnani, Laura, Giuggioli, Dilia, Dagna, Lorenzo, Tavoni, Antonio, Ursini, Francesco, L'Andolina, Massimo, Caso, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Bosco, Ylenia Dal, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Monti, Monica, Lorini, Serena, Aprile, Maria Letizia, Tasso, Marco, Miccoli, Mario, Bosello, Silvia Laura, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Matucci-Cerinic, Marco, Iannone, Florenzo, Giacomelli, Roberto, Salvarani, Carlo, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, and Bosello, Silvia (ORCID:0000-0002-4837-447X)

Abstract

Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored

Published
2022

45. Evidence for charge-based mimicry in anti dsDNA antibody generation

Author

Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, and Ghiggeri, Gian Marco

Abstract

Mechanisms for the generation of anti-dsDNA autoantibodies are still not completely elucidated. One theory states that dsDNA interacts for mimicry with antibodies raised versus other antigens but molecular features for mimicry are unknown. Here we show that, at physiological acid-base balance, anti-Annexin A1 binds IgG2 dsDNA in a competitive and dose-dependent way with Annexin A1 and that the competition between the two molecules is null at pH 9. On the other hand, these findings also show that dsDNA and Annexin A1 interact with their respective antibodies on a strictly pH-dependent basis: in both cases, the binding was minimal at pH 4 and maximal at pH9-10. The anionic charge of dsDNA is mainly conferred by the numerous phosphatidic residues. The epitope binding site of Annexin A1 for anti-Annexin A1 IgG2 was here characterized as a string of 34 amino acids at the NH2 terminus, 10 of which are anionic. Circulating levels of anti-dsDNA and anti-Annexin A1 IgG2 antibodies were strongly correlated in patients with systemic lupus erythematosus (n 496) and lupus nephritis (n 425) stratified for age, sex, etc. These results show that dsDNA competes with Annexin A1 for the binding with anti-Annexin A1 IgG2 on a dose and charged mediated base, being able to display an inhibition up to 75%. This study provides the first demonstration that dsDNA may interact with antibodies raised versus other anionic molecules (anti-Annexin A1 IgG2) because of charge mimicry and this interaction may contribute to anti-dsDNA antibodies generation.

Published
2022

47. Brief Report: Association of Natural Killer Cell Ligand Polymorphism HLA–C Asn80Lys With the Development of Anti‐SSA/Ro–Associated Congenital Heart Block

Author

Ainsworth, Hannah C., Marion, Miranda C., Bertero, Tiziana, Brucato, Antonio, Cimaz, Rolando, Costedoat‐Chalumeau, Nathalie, Fredi, Micaela, Gaffney, Patrick, Kelly, Jennifer, Levesque, Kateri, Maltret, Alice, Morel, Nathalie, Ramoni, Veronique, Ruffatti, Amelia, Langefeld, Carl D., Buyon, Jill P., and Clancy, Robert M.

Published
2017
Full Text
View/download PDF

49. Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation

Author

Tani, Chiara, primary, Elefante, Elena, additional, Arnaud, Laurent, additional, Barreira, Sofia C., additional, Bulina, Inita, additional, Cavagna, Lorenzo, additional, Costedoat-Chalumeau, Nathalie, additional, Doria, Andrea, additional, Fonseca, João Eurico, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Iaccarino, Luca, additional, Limper, Maarten, additional, Majnik, Judit, additional, Nagy, Gyorgy, additional, Pamfil, Cristina, additional, Rednic, Simona, additional, Reynolds, John A., additional, Tektonidou, Maria G., additional, Troldborg, Anne, additional, Zanframundo, Giovanni, additional, and Mosca, Marta, additional

Published
2022
Full Text
View/download PDF

50. Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres

Author

Moschetti, Liala, primary, Dal Pozzolo, Luisa, additional, Le Guern, Veronique, additional, Morel, Nathalie, additional, Yelnik, Cecile M., additional, Lambert, Marc, additional, Hachulla, Eric, additional, Benhamou, Ygal, additional, Nalli, Cecilia, additional, Fredi, Micaela, additional, Franceschini, Franco, additional, Andreoli, Laura, additional, Costedoat-Chalumeau, Nathalie, additional, and Tincani, Angela, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results